For postoperative body fluid management and postoperative complication prevention Torbaptan's effectiveness

Esaki Jiro0 个研究点目标入组 200 人开始时间: 2023年7月20日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1) Patients planning to perform open heart surgery under a heart-lung machine
•2) Patients who are aged 20 or older when acquiring consent
•3) Patients who have obtained document consent with their own freedom after fully understood participation in this research

•1)Patients who underwent emergency surgery
•2)Patients with a history of hypersensitivity to tolvaptan components or similar
•compounds (such as mozavaptan hydrochloride)
•3)Patients receiving desmopressin acetate hydrate (nocturia due to nocturia in men)
•4)Patients with a history of hypersensitivity to sulfonamide derivatives
•5)Patients with heart failure and markedly decreased EF (EF<30%)
•6)Patients with chronic renal dysfunction on dialysis
•7)Patients with liver cirrhosis
•8)Patients who underwent thoracoabdominal aortic replacement or heart-beating coronary artery bypass surgery alone
•9)Patients who are already using tolvaptan including oral medicines and injections at
•the time of informed consent
•10)Patients who need to use carperitide at the time of informed consent or throughout the study period
•11)Patients who cannot feel thirst or have difficulty in taking fluids
•12)Patients with hypernatremia (Na>148 mEq/L) before tolvaptan administration
•13)Patients with hyperkalemia (K>5.3 mEq/L) before tolvaptan administration
•14)Patients who are pregnant or may be pregnant
•15)Patients who are participating in or planning to participate in other clinical trials (intervention stu dies) or clinical trials
•16)Patients who are judged by the investigator (subinvestigator) to be inappropriate for participation in this

发起方

Esaki Jiro